The treatment of hemophilia A patients with inhibitor could be very expensive. Ankaferd blood stopper (ABS) is a unique folkloric medicinal plant extract, which has historically been used in Turkish traditional medicine as a hemostatic agent. In this article, a 16-year-old boy was presented with uncontrolled bleeding, despite the treatment of factor VIII, rVIIa, factor VIII inhibitor bypass activity (FEIBA), cyclophosphamide, and prednisolone at circumcision site that resolved with ABS in minutes. Our patient with hemophilia A and inhibitor is the first clinical pediatric case.
Scott JP, Montgomery RRHemorrhagic and thrombotic diseases. In: Kliegman RM, ed. Nelson Textbook of Pediatrics. 17th ed. Philadelphia: WB Saunders Company; 2007:1504-1525.
2.
Goker H., Haznedaroglu IC, Ercetin S., et al. Haemostatic actions of the folkloric medicinal plant extract Ankaferd blood stopper. J Int Med Res. 2008 ;36(1):163-170.
3.
Cipil H., Kosar A., Kaya A., et al. In vivo hemostatic effect of the medicinal plant extract Ankaferd blood stopper in rats pretreated with warfarin. Clin Appl Thromb Hemost. 2008. [Epub ahead of print].
Kurt M., Disibeyaz S., Akdogan M., Sasmaz N., Aksu S., Haznedaroglu ICEndoscopic application of Ankaferd blood stopper as a novel experimental treatment modality for upper gastrointestinal bleeding: a case report. Am J Gastroenterol. 2008; 103(8):2156-2158.
6.
Ibis M., Kurt M., Onal IK, Haznedaroglu ICSuccessful management of bleeding due to solitary rectal ulcer via topical application of Ankaferd blood stopper. J Altern Complement Med. 2008; 14(9):1073-1074.
7.
Kurt M., Kacar S., Onal IK, Akdogan M., Haznedaroglu ICAnkaferd blood stopper as an effective adjunctive hemostatic agent for the management of life-threatening arterial bleeding of the digestive tract. Endoscopy. 2008;40(suppl 2):262.
Kurt M., Oztas E., Kuran S., Onal IK, Kekilli M., Haznedaroglu ICTandem oral, rectal, and nasal administrations of Ankaferd blood stopper to control profuse bleedings leading to hemodynamic instability. Am J Emergency Med. ; IN PRESS.
10.
Dargaud Y., Lambert T., Trossaert M.New advances in the therapeutic and laboratory management of patients with haemophilia and inhibitors. Haemophilia. 2008 ;14(suppl 4):20-27.
11.
Ghosh K., Shetty S., Jijina F., Mohanty D.Role of epsilon amino caproic acid in the management of haemophilic patients with inhibitors. Haemophilia. 2004;10(1): 58-62.
12.
Robbins D., Kulkarni R., Gera R., Scott-Emuakpor AB, Bosma K., Penner JASuccessful treatment of high titer inhibitors in mild hemophilia A with avoidance of factor VIII and immunosuppressive therapy. Am J Hematol . 2001;68(3):184-188.
13.
Rech J., Hueber AJ, Leipe J., Manger B., Schett G., Kallert S.A case report of plasma exchange, steroids, mycophenolate mofetil and cyclophosphamide in acquired factor VIII inhibitors. Ther Apher Dial. 2008;12(5):406-408.
14.
Narukawa N. , Abe T., Shouno M., et al. A case of factor VIII inhibitor-positive acquired hemophilia treated by plasmapheresis. Ther Apher . 1999;3(4):323-325.
15.
Wiestner A. , Cho HJ, Asch AS, et al. Rituximab in the treatment of acquired factor VIII inhibitors. Blood. 2002;100(9):3426-3428.
16.
Sallah S., Wan JYEfficacy of 2-chlorodeoxyadenosine in refractory factor VIII inhibitors in persons without hemophilia. Blood. 2003;101(3):943-945.
